Qualigen Therapeutics, Inc. (QLGN) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Qualigen Therapeutics, Inc. is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's current operations consist of one early-clinical-stage therapeutic program (QN-302) and one preclinical program (Pan-RAS). The company previously operated a diagnostics business (Qualigen, Inc.) and held a majority interest in NanoSynex, Ltd., both of which were divested or deconsolidated in July 2023 and are now reported as discontinued operations.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 (Continuing Ops) |
| Total Expenses | $1,740,771 | $3,166,091 | $6,252,531 |
| Net Loss (Continuing Ops) | $(1,476,558) | $(3,509,309) | $(6,772,423) |
| Net Loss (Total) | $(1,576,558) | $(3,609,309) | $(7,614,938) |
| Cash and Cash Equivalents | $118,685 | $118,685 | $590,636 |
| Total Current Liabilities | $4,812,273 | $4,812,273 | $4,136,805 |
| Convertible Debt (Current) | $1,670,011 | $1,670,011 | $1,299,216 |
| Stockholders' Deficit | $(4,277,863) | $(4,277,863) | $(2,103,557) |
Note: The company has no revenue from continuing operations. Discontinued operations generated a loss of $100,000 in Q2 2024 due to an escrow settlement.
Material Changes vs. Prior Period
- Expense Reduction: Total expenses decreased significantly compared to the prior year. General and Administrative (G&A) expenses dropped 59% quarter-over-quarter (QoQ) and 46% year-over-year (YoY), primarily due to reduced stock-based compensation, payroll, and professional fees. Research and Development (R&D) expenses decreased 36% QoQ and 54% YoY, driven by lower program costs for QN-302 and Pan-RAS, partially offset by new costs related to the Marizyme co-development agreement.
- Non-Cash Gains: The company recorded significant non-cash gains on the change in fair value of warrant liabilities ($493,206 in Q2 2024) and derivative liabilities ($10,116 in Q2 2024), which reduced the reported net loss. These gains are driven by declines in the company's stock price.
- Debt and Equity Activity: The company issued convertible debentures totaling approximately $1.65 million in principal during the first half of 2024. Significant non-cash transactions included the conversion of debt into common stock and monthly redemptions of debt paid in shares.
- Liquidity Position: Cash balances declined from $401,803 at year-end 2023 to $118,685 at June 30, 2024, reflecting a net cash burn of $2.3 million from operating activities in the first six months of 2024.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the one-year period following the report date. Current cash is expected to fund operations only into the fourth quarter of 2024. The company requires additional financing to continue operations.
- Recent Financing: Subsequent to the reporting period (July 2024), the company raised $2.0 million via an 18% Senior Note and settled approximately $319,000 of accounts payable for $50,000 cash.
- Nasdaq Compliance: The company received a delisting notice from Nasdaq regarding non-compliance with the minimum bid price ($1.00) and minimum stockholders' equity ($2.5 million) requirements. A hearing panel granted an extension until October 31, 2024, to regain compliance. Failure to comply may result in delisting.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, specifically regarding insufficient accounting personnel and lack of effective IT general controls. These weaknesses were not remediated during the quarter.
- Strategic Partnership: The company entered a Co-Development Agreement with Marizyme, Inc., providing up to $1.75 million in funding in exchange for royalty-like payments on Marizyme's DuraGraft product sales.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $2.0 million raised in July 2024 to extend the operating runway beyond Q4 2024, given the high interest rate (18%) on the new senior note.
- Nasdaq Status: Monitor the company's progress in regaining compliance with Nasdaq listing standards by the October 31, 2024 deadline to avoid delisting.
- Dilution Risk: Assess the impact of outstanding convertible debt and warrants (over 9.7 million shares reserved) on future dilution, especially given the low conversion prices ($0.26 - $0.61) and ratchet provisions.
- Internal Controls: Evaluate the timeline and cost required to remediate the material weaknesses in internal controls, which currently affect the reliability of financial reporting.
- Debt Obligations: Review the terms of the 2022 and 2024 Convertible Debentures, including mandatory monthly redemption features and the potential for further share issuance in lieu of cash payments.